Cargando…

Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions

We propose a novel framework for determining radiomics feature robustness by considering the effects of both biological and noise signals. This framework is preliminarily tested in a study predicting the epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Lin, Sun, Shawn H., Afran, Aaron, Yang, Hao, Lu, Zheng Feng, So, James, Schwartz, Lawrence H., Zhao, Binsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934702/
https://www.ncbi.nlm.nih.gov/pubmed/33681463
http://dx.doi.org/10.3390/tomography7010005
_version_ 1783660867361964032
author Lu, Lin
Sun, Shawn H.
Afran, Aaron
Yang, Hao
Lu, Zheng Feng
So, James
Schwartz, Lawrence H.
Zhao, Binsheng
author_facet Lu, Lin
Sun, Shawn H.
Afran, Aaron
Yang, Hao
Lu, Zheng Feng
So, James
Schwartz, Lawrence H.
Zhao, Binsheng
author_sort Lu, Lin
collection PubMed
description We propose a novel framework for determining radiomics feature robustness by considering the effects of both biological and noise signals. This framework is preliminarily tested in a study predicting the epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients. Pairs of CT images (baseline, 3-week post therapy) of 46 NSCLC patients with known EGFR mutation status were collected and a FDA-customized anthropomorphic thoracic phantom was scanned on two vendors’ scanners at four different tube currents. Delta radiomics features were extracted from the NSCLC patient CTs and reproducible, non-redundant, and informative features were identified. The feature value differences between EGFR mutant and EGFR wildtype patients were quantitatively measured as the biological signal. Similarly, radiomics features were extracted from the phantom CTs. A pairwise comparison between settings resulted in a feature value difference that was quantitatively measured as the noise signal. Biological signals were compared to noise signals at each setting to determine if the distributions were significantly different by two-sample t-test, and thus robust. Four optimal features were selected to predict EGFR mutation status, Tumor-Mass, Sigmoid-Offset-Mean, Gabor-Energy and DWT-Energy, which quantified tumor mass, tumor-parenchyma density transition at boundary, line-like pattern inside tumor and intratumoral heterogeneity, respectively. The first three variables showed robustness across the majority of studied CT acquisition parameters. The textual feature DWT-Energy was less robust. The proposed framework was able to determine robustness of radiomics features at specific settings by comparing biological signal to noise signal. Identification of robust radiomics features may improve the generalizability of radiomics models in future studies.
format Online
Article
Text
id pubmed-7934702
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79347022021-03-06 Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions Lu, Lin Sun, Shawn H. Afran, Aaron Yang, Hao Lu, Zheng Feng So, James Schwartz, Lawrence H. Zhao, Binsheng Tomography Article We propose a novel framework for determining radiomics feature robustness by considering the effects of both biological and noise signals. This framework is preliminarily tested in a study predicting the epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients. Pairs of CT images (baseline, 3-week post therapy) of 46 NSCLC patients with known EGFR mutation status were collected and a FDA-customized anthropomorphic thoracic phantom was scanned on two vendors’ scanners at four different tube currents. Delta radiomics features were extracted from the NSCLC patient CTs and reproducible, non-redundant, and informative features were identified. The feature value differences between EGFR mutant and EGFR wildtype patients were quantitatively measured as the biological signal. Similarly, radiomics features were extracted from the phantom CTs. A pairwise comparison between settings resulted in a feature value difference that was quantitatively measured as the noise signal. Biological signals were compared to noise signals at each setting to determine if the distributions were significantly different by two-sample t-test, and thus robust. Four optimal features were selected to predict EGFR mutation status, Tumor-Mass, Sigmoid-Offset-Mean, Gabor-Energy and DWT-Energy, which quantified tumor mass, tumor-parenchyma density transition at boundary, line-like pattern inside tumor and intratumoral heterogeneity, respectively. The first three variables showed robustness across the majority of studied CT acquisition parameters. The textual feature DWT-Energy was less robust. The proposed framework was able to determine robustness of radiomics features at specific settings by comparing biological signal to noise signal. Identification of robust radiomics features may improve the generalizability of radiomics models in future studies. MDPI 2021-02-09 /pmc/articles/PMC7934702/ /pubmed/33681463 http://dx.doi.org/10.3390/tomography7010005 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lu, Lin
Sun, Shawn H.
Afran, Aaron
Yang, Hao
Lu, Zheng Feng
So, James
Schwartz, Lawrence H.
Zhao, Binsheng
Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions
title Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions
title_full Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions
title_fullStr Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions
title_full_unstemmed Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions
title_short Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions
title_sort identifying robust radiomics features for lung cancer by using in-vivo and phantom lung lesions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934702/
https://www.ncbi.nlm.nih.gov/pubmed/33681463
http://dx.doi.org/10.3390/tomography7010005
work_keys_str_mv AT lulin identifyingrobustradiomicsfeaturesforlungcancerbyusinginvivoandphantomlunglesions
AT sunshawnh identifyingrobustradiomicsfeaturesforlungcancerbyusinginvivoandphantomlunglesions
AT afranaaron identifyingrobustradiomicsfeaturesforlungcancerbyusinginvivoandphantomlunglesions
AT yanghao identifyingrobustradiomicsfeaturesforlungcancerbyusinginvivoandphantomlunglesions
AT luzhengfeng identifyingrobustradiomicsfeaturesforlungcancerbyusinginvivoandphantomlunglesions
AT sojames identifyingrobustradiomicsfeaturesforlungcancerbyusinginvivoandphantomlunglesions
AT schwartzlawrenceh identifyingrobustradiomicsfeaturesforlungcancerbyusinginvivoandphantomlunglesions
AT zhaobinsheng identifyingrobustradiomicsfeaturesforlungcancerbyusinginvivoandphantomlunglesions